Association between chemotherapy-induced neutropenia at 1-month and overall survival in patients receiving TAS-102 for metastatic colorectal cancer

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter D. Kotani
Citation Annals of Oncology (2016) 27 (2): 102-117. 10.1093/annonc/mdw200
Authors D. Kotani1, K. Pashtoon2, M. Cecchini3, K. Shitara1, A. Ohtsu1, R. Ramanathan4, H. Hochster3, A. Grothey5, T. Yoshino1
  • 1National Cancer Center Hospital East, Kashiwa, Japan, /
  • 2Mayo Clinic, Rochester, Minnesota, USA, /
  • 3Yale Cancer Center, New Haven, Connecticut, USA, /
  • 4Mayo Clinic, Scottsdale, Arizona, USA, /
  • 5Mayo Clinic, Rochester, New York, USA, /


Favorable outcomes have been reported in patients with several types of cancers who had chemotherapy-induced neutropenia (CIN). TAS-102 (trifluridine and tipiracil hydrochloride; a novel combination oral nucleoside anti-tumor agent) was first approved in Japan on March 2014 and received US. Food and Drug Administration (FDA) approval on September 2015 after a global phase 3 RECOURSE trial in patients with metastatic colorectal cancer (mCRC). Exposure-dependent incorporation of trifluridine as an antitumor component of TAS-102 into DNA of tumors as well as white blood cells in preclinical model suggests CIN may serve as a potential surrogate of TAS-102 efficacy.